ArticleRadiology2018
Science to Practice: Decrypting the Enigma of Ablation-induced Off-Target Effects-Is Network Pathway Analysis the Final Piece of the Puzzle?
Article in Radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy.Abdominal radiology (New York) · 2021Review
Corrections and comments
- Comment on
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As part of the ongoing effort to better understand and mitigate pro-oncogenic off-target effects of imaging-guided radiofrequency ablation (RFA), Kumar et al ( 1 ) used gene expression and network pathway analysis to examine the gene activation profiles in the peri-ablational zone after RFA in a breast adenocarcinoma liver metastasis animal model. Their analysis identified STAT3 (signal transducer and activator of transcription 3) as a key transcription factor upregulated in many signaling pathways in the peri-ablational zone after RFA. Consequently, the authors successfully used two STAT3 inhibitors to reduce distant tumor growth after treatment with RFA. By demonstrating that judicious and appropriate adjuvant therapy helped contain distant tumor growth caused by ablation, Kumar et al have managed to pave the road ahead for the definitive success of ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.